Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer (TESEGAST)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by Genta Incorporated.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Genta Incorporated
ClinicalTrials.gov Identifier:
NCT01573468
First received: April 5, 2012
Last updated: July 20, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2014
  Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)